MCRB
Seres Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.72
+1.42%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.9M | 789.0K | — | — | — |
| Cost of Revenue | 328.0K | 4.1M | 3.5M | 19.3M | — |
| Gross Profit | 1.6M | (3.3M) | (3.5M) | (19.3M) | — |
| Operating Expenses | |||||
| R&D Expense | 46.6M | 49.1M | 64.6M | 117.6M | 109.7M |
| SG&A Expense | 32.1M | 39.2M | 53.2M | 77.5M | 70.3M |
| General & Admin Expense | 32.1M | 39.2M | 53.2M | 77.5M | 70.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 6.8M | 2.4M | — | (19.3M) | — |
| Total Operating Expenses | 85.6M | 90.6M | 117.8M | 175.8M | 179.9M |
| Cost and Expenses | 85.9M | 94.8M | 121.3M | 195.1M | 179.9M |
| Operating Income (EBIT) | (84.0M) | (94.0M) | (121.3M) | (195.1M) | (179.9M) |
| Non-Operating | |||||
| Interest Income | 1.6M | 2.2M | 4.0M | 7.3M | 3.1M |
| Interest Expense | — | — | — | 13.2M | 6.0M |
| Net Interest Income | 1.6M | 2.2M | 4.0M | (5.9M) | (3.0M) |
| Other Non-Op Income/Expense | 61.6M | 99.7M | (4.5M) | 5.0M | (3.7M) |
| Non-Operating Income (excl Interest) | (35.7M) | (99.7M) | 4.5M | (7.4M) | (2.4M) |
| EBT (Pre-Tax Income) | (22.5M) | 5.7M | (125.8M) | (190.1M) | (183.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (22.5M) | 5.7M | (146.6M) | (113.7M) | (250.2M) |
| Earnings from Cont. Ops | (22.5M) | 5.7M | (125.8M) | (190.1M) | (183.6M) |
| Earnings from Discont. Ops | — | — | (20.8M) | 76.4M | (66.6M) |
| Bottom Line Net Income | (22.5M) | 5.7M | (146.6M) | (113.7M) | (250.2M) |
| Per Share | |||||
| Basic EPS | ($2.42) | $0.64 | ($18.86) | ($17.77) | ($46.29) |
| Diluted EPS | ($2.41) | $0.64 | ($18.86) | ($17.77) | ($46.29) |
| Revenue Per Share | $0.20 | $0.09 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 9.6M | 8.9M | 7.8M | 6.4M | 5.4M |
| Diluted Shares Outstanding | 9.6M | 8.9M | 7.8M | 6.4M | 5.4M |
| Profitability Metrics | |||||
| EBITDA | (44.3M) | 9.8M | (120.3M) | (181.4M) | (170.9M) |
| D&A | 4.0M | 4.1M | 5.5M | 6.2M | 6.6M |
| EBIT | (48.3M) | 5.7M | (125.8M) | (187.7M) | (177.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026